Plain-English translation of NCT04626791 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mantle Cell Lymphoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for mantle cell lymphoma using a medication called combined with chemotherapy drugs (, , , doxorubicin, and ). The goal is to see how well this medication combination works as a first-line treatment for patients who may eventually need a stem cell transplant. Researchers want to measure how many patients achieve a complete response and to understand how safe this treatment is.
Mantle cell lymphoma is an aggressive blood cancer, and doctors are looking for better first-line treatments that can help patients before they undergo stem cell transplant. This trial exists to test whether combining with traditional chemotherapy offers improved outcomes compared to older treatment approaches.
You would receive six 3-week treatment cycles, alternating between two different drug schedules. In cycles 1, 3, and 5, you would take the medication by mouth twice daily and receive four drugs by injection or IV on day 1, plus pills for five days. In cycles 2, 4, and 6, you would take the medication by mouth twice daily and receive two drugs by IV on days 1–2. After completing the six cycles, you would be followed with scans and blood tests every 6 months for up to 2 years to monitor your response and any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States